No price range yet · latest SEC filing Oct 9, 2026.
Pinch-zoom for details.
Clinical-stage drug developer working on treatments for scarring (fibrosis).
Fiscal year
1st half
Quarter
Fiscal year
1st half
Quarter
| $ | FY2024 | FY2025 | YoY | H1 2025 | H1 2026 | Change | Q 2024 |
|---|---|---|---|---|---|---|---|
| Operating result | (3.35M) | (3.46M) | −3.3% | (1.20M) | (1.19M) | +0.5% | (853K) |
| Net result | (3.36M) | (4.55M) | −35.6% | (1.41M) | (1.25M) | +11.4% | (893K) |
| $ | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Operating result | (3.35M) | (3.46M) | −3.3% |
| Net result | (3.36M) | (4.55M) | −35.6% |
| $ | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Operating result | (1.20M) | (1.19M) | +0.5% |
| Net result | (1.41M) | (1.25M) | +11.4% |
| $ | Q 2024 |
|---|---|
| Operating result | (853K) |
| Net result | (893K) |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
The filing's own risk-factor headings, shortened.
The filing's own strategy headings, shortened.
Source: BirchBioMed Inc.'s Form S-1/A, filed with the SEC on Oct 9, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back